iPS reprogramming was accomplished using an episomal expression system containing a proprietary mix of vectors (Oct-4, Sox-2, Klf-4 along with p53 Anti-sense, EBNA-1). The target cell was obtained from an 8 year Caucasian female and sibling to CET.IPS. FFNPC-01. This patient had evidence of splenomegaly without neurological symptoms at time of presentation and subsequently received intravenous and intrathecal cyclodextrin. Cell line is shipped with dry ice.